CD33 and acute myeloid leukemia: Previous reports tested combined antigen targeting of MOLM-13, HL-60 and KG1a AML cell lines and noted improved survival following combined dosing with anti-CD33 and anti-CLL-1 CAR T cells compared to monotherapy options [42].